Quintiles has expanded its bioanalytical lab services with the establishment of a GLP-compliant bioanalytical liquid chromatography-mass spectrometry (LC-MS) lab in Oss, the Netherlands. The Oss lab is led by Dr. Benno Ingelse, an industry expert with more than 15 years of bioanalytical experience. Additionally, the new lab will enhance Quintiles’ clinical trial lab services.
 
“Adding this capability in Europe is a key step for our bioanalytical business and supports the strategy to increase our participation in the substantial European bioanalytical market,” said Costa Panagos, senior vice president and global head of Global Central Laboratories at Quintiles. “This is an exciting milestone for Quintiles and specifically our lab business as we expand our capabilities while continuing to provide the value and high-quality service our customers require.”
 
Currently, Quintiles’ bioanalytical and ADME capabilities are managed out of three lab sites in the U.S. The new lab will be fully integrated with Quintiles’ existing laboratory in Ithaca, NY, enabling the transfer of assays back and forth to accommodate global studies. The Oss lab will become part of the recent clinical trials lab services joint venture with Quest Diagnostics. That transaction is anticipated to close in 3Q15. 
 
“The Oss lab will further enhance the scale, clinical trial expertise and diverse therapeutic experience that will be a cornerstone of the proposed joint venture with Quest Diagnostics,” said Panagos, who will serve as the new joint venture’s chief executive officer upon completion of the transaction. “The addition of the Oss laboratory is integral to the continued evolution of our laboratory business and we’re excited about the benefits it can provide as part of a globally scaled and agile business for our customers today as well as in the future.”